Header Logo

Connection

Nirav Shah to Retrospective Studies

Back to Details
This is a "connection" page, showing publications Nirav Shah has written about Retrospective Studies.
Nirav Shah
Connection Strength
0.391
Retrospective Studies
  1. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 11; 24(11):1488-1495.
    View in: PubMed
    Score: 0.044
  2. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 02; 19(2):95-102.
    View in: PubMed
    Score: 0.042
  3. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 01; 25(1):e33-e38.
    View in: PubMed
    Score: 0.041
  4. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 02; 180(4):534-544.
    View in: PubMed
    Score: 0.039
  5. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
    View in: PubMed
    Score: 0.015
  6. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 03; 59(3):373-379.
    View in: PubMed
    Score: 0.015
  7. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 03; 30(3):285-297.
    View in: PubMed
    Score: 0.015
  8. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):254-259.
    View in: PubMed
    Score: 0.015
  9. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 11 09; 16(1):111.
    View in: PubMed
    Score: 0.015
  10. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023 Jun 27; 7(12):2657-2669.
    View in: PubMed
    Score: 0.014
  11. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):863-868.
    View in: PubMed
    Score: 0.013
  12. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479.
    View in: PubMed
    Score: 0.012
  13. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
    View in: PubMed
    Score: 0.012
  14. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 01 14; 4(1):47-54.
    View in: PubMed
    Score: 0.011
  15. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec; 26(4):210-215.
    View in: PubMed
    Score: 0.011
  16. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
    View in: PubMed
    Score: 0.011
  17. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 07; 24(7):955-962.
    View in: PubMed
    Score: 0.010
  18. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 04; 25(4):827-833.
    View in: PubMed
    Score: 0.010
  19. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401.
    View in: PubMed
    Score: 0.010
  20. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 09; 53(9):1210-1213.
    View in: PubMed
    Score: 0.010
  21. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1955-1960.
    View in: PubMed
    Score: 0.009
  22. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05; 17(5):305-311.e2.
    View in: PubMed
    Score: 0.009
  23. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int. 2013 Jun; 26(6):616-22.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.